Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs.

Lee HJ, Hur YK, Cho YD, Kim MG, Lee HT, Oh YK, Kim YB.

PLoS One. 2012;7(11):e50296. doi: 10.1371/journal.pone.0050296. Epub 2012 Nov 27.


Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1.

Lee HJ, Park N, Cho HJ, Yoon JK, Van ND, Oh YK, Kim YB.

Vaccine. 2010 Feb 10;28(6):1613-9. doi: 10.1016/j.vaccine.2009.11.044. Epub 2009 Dec 2.


Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus.

Han SE, Kim MG, Lee S, Cho HJ, Byun Y, Kim S, Kim YB, Choi Y, Oh YK.

J Appl Toxicol. 2013 Dec;33(12):1474-83. doi: 10.1002/jat.2815. Epub 2012 Sep 14.


Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.

Cho H, Lee HJ, Heo YK, Cho Y, Gwon YD, Kim MG, Park KH, Oh YK, Kim YB.

PLoS One. 2014 Apr 23;9(4):e95961. doi: 10.1371/journal.pone.0095961. eCollection 2014.


Preclinical pharmacokinetics and biodistribution of human papillomavirus DNA vaccine delivered in human endogenous retrovirus envelope-coated baculovirus vector.

Cho HJ, Lee S, Im S, Kim MG, Lee J, Lee HJ, Lee KH, Kim S, Kim YB, Oh YK.

Pharm Res. 2012 Feb;29(2):585-93. doi: 10.1007/s11095-011-0598-z. Epub 2011 Sep 23.


Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009.

Choi JY, Gwon YD, Kim JK, Cho YD, Heo YK, Cho HS, Choi TJ, Poo HR, Oh YK, Kim YB.

PLoS One. 2013 Nov 18;8(11):e80762. doi: 10.1371/journal.pone.0080762. eCollection 2013.


Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge.

Lee HJ, Cho H, Kim MG, Heo YK, Cho Y, Gwon YD, Park KH, Jin H, Kim J, Oh YK, Kim YB.

PLoS One. 2015 Mar 19;10(3):e0119408. doi: 10.1371/journal.pone.0119408. eCollection 2015.


Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G; HPV-010 Study Group.

Hum Vaccin. 2009 Oct;5(10):705-19. Epub 2009 Oct 14.


Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.

Han JE, Wui SR, Park SA, Lee NG, Kim KS, Cho YJ, Kim HJ, Kim HJ.

Vaccine. 2012 Jun 13;30(28):4127-34. doi: 10.1016/j.vaccine.2012.04.079. Epub 2012 May 1.


Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types.

Zhang T, Xu Y, Qiao L, Wang Y, Wu X, Fan D, Peng Q, Xu X.

Vaccine. 2010 Apr 26;28(19):3479-87. doi: 10.1016/j.vaccine.2010.02.057. Epub 2010 Mar 6.


[The preliminary analysis on immunogenicity of DNA vaccines against human papillomavirus 58].

Wu XL, Nie JH, Zhang CT, Wu Y, Zhao CY, Wang YC.

Bing Du Xue Bao. 2008 May;24(3):196-201. Chinese.


Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.

J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.


Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G; HPV-010 Study Group.

Hum Vaccin. 2011 Dec;7(12):1343-58. doi: 10.4161/hv.7.12.18281. Epub 2011 Dec 1.


Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.

Lee HJ, Yoon JK, Heo Y, Cho H, Cho Y, Gwon Y, Kim KC, Choi J, Lee JS, Oh YK, Kim YB.

J Microbiol. 2015 Jun;53(6):415-20. doi: 10.1007/s12275-015-5150-0. Epub 2015 May 30.


Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.

Diniz MO, Lasaro MO, Ertl HC, Ferreira LC.

Clin Vaccine Immunol. 2010 Oct;17(10):1576-83. doi: 10.1128/CVI.00264-10. Epub 2010 Aug 25.


Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.

Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, Poo H.

Vaccine. 2012 May 9;30(22):3286-94. doi: 10.1016/j.vaccine.2012.03.009. Epub 2012 Mar 15.


Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.

Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D.

Clin Vaccine Immunol. 2007 Oct;14(10):1285-95. Epub 2007 Aug 8.


Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.

Zhou L, Zhu T, Ye X, Yang L, Wang B, Liang X, Lu L, Tsao YP, Chen SL, Li J, Xiao X.

Hum Gene Ther. 2010 Jan;21(1):109-19. doi: 10.1089/hum.2009.139.


Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants.

Cho HJ, Kim JY, Lee Y, Kim JM, Kim YB, Chun T, Oh YK.

Vaccine. 2010 Mar 19;28(14):2598-606. doi: 10.1016/j.vaccine.2010.01.013. Epub 2010 Jan 28.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk